anti-PD-1 antibody
Showing 1 - 25 of >10,000
Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)
Not yet recruiting
- Stage IIIA Hepatocellular Carcinoma
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- (no location specified)
Sep 24, 2023
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite
Completed
- Metastatic Colorectal Adenocarcinoma
- regorafenib plus anti-PD-1 antibodies
-
Changsha, Hunan, ChinaHunan Cancer hospital
Jul 4, 2023
Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:
Not yet recruiting
- Hepatocellular Carcinoma Non-resectable
- transarterial therapies
- (no location specified)
Nov 27, 2022
Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)
Not yet recruiting
- Solid Tumor, Adult
- +2 more
- HST-1011
- Cemiplimab
- (no location specified)
Dec 14, 2022
Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Refractory Non-Small Cell Lung Cancer
- Daratumumab
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023
Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)
Not yet recruiting
- Colorectal Cancer
- Serplulimab + FOLFOXIRI
- Radiation therapy
- (no location specified)
Oct 24, 2023
TNBC - Triple-Negative Breast Cancer Trial in Beijing (Eribulin, anti-PD-1 antibody)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Eribulin
- anti-PD-1 antibody
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
May 29, 2022
Hepatocellular Carcinoma Trial in Beijing (Sintilimab, Lenvatinib, radiotherapy)
Recruiting
- Hepatocellular Carcinoma
- Sintilimab
- +2 more
-
Beijing, Beijing, ChinaBeijing Tsinghua Changgung Hospital
Jan 5, 2023
Relapsed or Refractory DLBCL Trial (Anti-PD-1 Antibody Plus Chidamide and Rituximab)
Not yet recruiting
- Relapsed or Refractory DLBCL
- Anti-PD-1 Antibody Plus Chidamide and Rituximab
- (no location specified)
Apr 6, 2022
Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)
Not yet recruiting
- Cervical Cancer
- Anti-PD-1 antibody balstilimab
-
Amsterdam, NetherlandsAmsterdam UMC
Oct 17, 2023
NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)
Terminated
- Non-small Cell Lung Cancer
- REGN2810/ipi
- +2 more
-
Saint Petersburg, Florida
- +2 more
Oct 22, 2022
Basal Cell Carcinoma Trial in Zürich (Cemiplimab Injection [Libtayo])
Recruiting
- Basal Cell Carcinoma
- Cemiplimab Injection [Libtayo]
-
Zürich, SwitzerlandUniversity Hospital Zurich, Clinic of Dermatology
Nov 3, 2022
Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNa Trial in Chongqing (Anti-PD-1 antibody, NAs, Peg-IFNa)
Not yet recruiting
- Chronic Hepatitis b
- +2 more
- Anti-PD-1 antibody
- +2 more
-
Chongqing, Chongqing, ChinaThe 2nd affiliated Hospital of Chongqing Medical University
Mar 14, 2023
Chronic Hepatitis b, Anti-PD-1 Antibody Trial in Chongqing (Anti-PD-1 antibody, NAs)
Not yet recruiting
- Chronic Hepatitis b
- Anti-PD-1 Antibody
- Anti-PD-1 antibody
- NAs
-
Chongqing, Chongqing, ChinaThe 2nd affiliated Hospital of Chongqing Medical University
Mar 3, 2023
Advanced Malignant Tumors Trial in China (LBL-019 Injection, anti-PD-1 antibody injection)
Recruiting
- Advanced Malignant Tumors
- LBL-019 Injection
- anti-PD-1 antibody injection
-
Wuhan, Hubei, China
- +4 more
Apr 26, 2022
Hepatocellular Carcinoma Trial in Shanghai (Sintilimab, TACE)
Recruiting
- Hepatocellular Carcinoma
- Sintilimab
- TACE
-
Shanghai, ChinaFudan University Shanghai Cancer Center
May 30, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Camrelizumab, US/CT-guided Percutaneous Cryoablation)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Camrelizumab
- US/CT-guided Percutaneous Cryoablation
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 1, 2022
Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer Trial in Fairfax (TNG260, Pembrolizumab)
Recruiting
- Non Small Cell Lung Cancer
- +6 more
-
Fairfax, VirginiaNEXT Oncology
Jun 7, 2023
Lenvatinib Combined Anti-PD1 Antibody for Advanced
Completed
- Hepatocellular Carcinoma
- +2 more
- Lenvatinib
- +6 more
-
Guangzhou, Guangdong, ChinaSecond Affiliated Hospital of Guangzhou Medical University
Jul 8, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,
Recruiting
- Recurrent Cervical Carcinoma
- +5 more
- Anti-PD-1 antibody camrelizumab
- Albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1
Completed
- Recurrent Cervical Carcinoma
- +4 more
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Melanoma (Skin) Trial in Tampa (biological, drug, procedure)
Active, not recruiting
- Melanoma (Skin)
- NY-ESO-1 157-165 (165V)
- +5 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 17, 2023
Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- PD-1 Inhibitors
-
Zhengzhou, Henan, ChinaFeng Wang
Oct 9, 2023